{"entity":{"id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of FH-006 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT06735144 by Jiangsu HengRui Medicine Co., Ltd., with 200 participants planned, started 2024-12-23 and due to reach its primary completion in 2027-12. Interventions recorded: FH-006.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06735144","url":"https://clinicaltrials.gov/study/NCT06735144"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06735144","phase":"1/2","setting":"A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":200,"outcomes":[]},"route":"/trials/nct06735144/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}